Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online:317
  • Home
  • Print this page
  • Email this page


 
 Table of Contents  
EDITORIAL
Year : 2021  |  Volume : 35  |  Issue : 2  |  Page : 95-96

Biomarkers of chronic pain: A tool for diagnosis and evaluation of management – Where do we stand?


1 Department of Biochemistry, Faculty of Life Sciences, Aligarh Muslim University, Aligarh, Uttar Pradesh, India
2 Department of Anaesthesiology and Critical Care, Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim University, Aligarh, Uttar Pradesh, India

Date of Web Publication31-Aug-2021

Correspondence Address:
Dr. Nazia Tauheed
Department of Anaesthesiology and Critical Care, Jawaharlal Nehru Medical College and Hospital, Aligarh Muslim University, Aligarh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijpn.ijpn_55_21

Rights and Permissions

How to cite this article:
Fatima S, Tauheed N. Biomarkers of chronic pain: A tool for diagnosis and evaluation of management – Where do we stand?. Indian J Pain 2021;35:95-6

How to cite this URL:
Fatima S, Tauheed N. Biomarkers of chronic pain: A tool for diagnosis and evaluation of management – Where do we stand?. Indian J Pain [serial online] 2021 [cited 2021 Dec 3];35:95-6. Available from: https://www.indianjpain.org/text.asp?2021/35/2/95/325205



With another milestone in history, as India completes 75 years of independence, long-term pain or chronic pain, as they call it, still nags a vast majority of our population. Even when there is a solitary precipitating event in the genesis of chronic pain (e.g., injury), there remains a combination of factors that affect its duration, intensity, and effects (physical, psychological, social, and emotional).[1]

Truly stated by Niculescu et al., blood biomarkers constitute a kind of liquid biopsy,[2] all the more significant in subjective clinical conditions, such as pain. The term “biomarker,” as defined by the National Institutes of Health Biomarkers Definitions Working Group, is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.[3]

Current advanced research suggests that genetic expression of cytokines (signaling proteins mediating activation, differentiation, and proliferation of immune cells), positively or negatively, correlates with the experience of chronic pain. They can be pro-inflammatory or anti-inflammatory, and a misaligned balance between the two has been a common finding in most of the studies conducted. Pro-inflammatory cytokines, such as interleukin-1β (IL-1β), IL-6, IL-2, IL-33, CCL3, CXCL1, CCR5, and tumor necrosis factor-alpha, have been found to play significant roles in the amplification of chronic pain states.[4] The anti-inflammatory ones include IL-4, IL-10, and transforming growth factor β1.

Whereas the world has taken leaps in research and evaluation of biomarkers, little of such research has been paid heed to at the national level. The role of cytokine in chronic pain states was observed in Germany in 2006.[5] In 2020, Gunn et al. have rightly concluded that abnormal biomarker findings provide objective support for the role of cytokine-mediated inflammation, oxidative stress, abnormally low production of neurotransmitters, and micronutrient deficiencies in the development or worsening of chronic pain.[6]

Although a few observations on the incidence and prevalence of chronic pain, the social burden, etc., have been reported from the subcontinent, little research has been done for the same. The recently reported research on the role of biomarkers in chronic pain has been published in 2020. This was a longitudinal observational study by Goel et al. who observed the frequency, patterns, and response to the treatment related to various biomarkers (biological and psychosocial) in patients of chronic nonspecific pain syndrome.[7]

Another notable well-designed, double-blind randomized controlled trial by Saxena et al. on an important biomarker, serum brain-derived neurotrophic factor (BDNF), was reported in 2016. BDNF levels were significantly decreased in patients of thoracic postherpetic neuralgia as compared to healthy volunteers. Subsequently, a significant rise in the levels was seen after a multimodal intervention using pregabalin therapy and pulsed radiofrequency of the intercostal nerves.[8]

On the international platform, the biopsychosocial model, which accounts for the dynamics and complex interactions among physiological, psychological, and social factors, has replaced the earlier biomedical approach of chronic pain. An evaluation of these interactions is being appreciated to tailor-specific treatment and prevention of chronic pain. The panel of functional pain biomarkers with predictive abilities can be beneficial as it provides practitioners with novel, objective insight into the contributors of pain, paving the way for a truly personalized pain medicine.

The Indian subcontinent, with a population as diverse as the entire world, now needs to put the foot down, to accelerate if not overtake in the researches on chronic pain biomarkers. An approach to management based merely on international research and data would have a much-varied outcome in a population diversity almost as extensive as the biodiversity worldwide, a call to the pain physicians to venture into this lapsed, unrecalled domain.



 
  References Top

1.
Mills SE, Nicolson KP, Smith BH. Chronic pain: A review of its epidemiology and associated factors in population-based studies. Br J Anaesth 2019;123:e273-83.  Back to cited text no. 1
    
2.
Niculescu AB, Le-Niculescu H, Levey DF, Roseberry K, Soe KC, Rogers J, et al. Towards precision medicine for pain: Diagnostic biomarkers and repurposed drugs. Mol Psychiatry 2019;24:501-22.  Back to cited text no. 2
    
3.
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.  Back to cited text no. 3
    
4.
Saxena AK, Bhardwaj N, Chilkoti GT, Malik A, Thakur GK, Bajaj M, et al. Modulation of mRNA expression of IL-6 and mTORC1 and efficacy and feasibility of an integrated approach encompassing cognitive behavioral therapy along with pregabalin for management of neuropathic pain in post herpetic neuralgia: A pilot study. Pain Med 2021; https://doi.org/10.1093/pm/pnab142.  Back to cited text no. 4
    
5.
Uçeyler N, Valenza R, Stock M, Schedel R, Sprotte G, Sommer C. Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum 2006;54:2656-64.  Back to cited text no. 5
    
6.
Gunn J, Hill MM, Cotten BM, Deer TR. An analysis of biomarkers in patients with chronic pain. Pain Physician 2020;23:E41-9.  Back to cited text no. 6
    
7.
Goel D, Garg S, Srivastav M, Gupta S, Kaur A. Biomarkers of chronic nonspecific pain syndrome: A cross-sectional hospital-based pilot study. Ind J Pain 2020;34:15-21.  Back to cited text no. 7
    
8.
Saxena AK, Lakshman K, Sharma T, Gupta N, Banerjee BD, Singal A. Modulation of serum BDNF levels in postherpetic neuralgia following pulsed radiofrequency of intercostal nerve and pregabalin. Pain Manag 2016;6:217-27.  Back to cited text no. 8
    




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
References

 Article Access Statistics
    Viewed602    
    Printed12    
    Emailed0    
    PDF Downloaded94    
    Comments [Add]    

Recommend this journal